Stomach Cancer, Gastroesophageal Junction Cancer (GEJ)
A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma
The main purpose of this study is to evaluate the effectiveness of S-1 and oxaliplatin with or without ramucirumab as first line therapy in participants with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Your participation could last up to 54 weeks depending on how you and your tumor respond.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
Participant must have a diagnosis of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, confirmed by histology or cytology; participants with esophageal cancer are not eligible
Participants of reproductive potential (men and woman) must agree to use contraception (hormonal or barrier methods) during the study period and at least 6 months after the last dose of study treatment
Participant must be willing to provide a blood sample for research purposes
Participant must not have human epidermal growth factor receptor 2 (HER2)-positive status
Participant must not have known brain metastases, leptomeningeal disease, or uncontrolled spinal cord compression
Female participant must not be pregnant or breast feeding. Females of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to first dose of study treatment
Participant must not have any prior malignancies